Author: p539124

04 October, 2022 Allgemein

Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming

19 September, 2022 Uncategorized

Pantherna among Pharma Trend award winners

05 September, 2022 Allgemein

Pantherna Therapeutics collaborates with Charité – Universitätsmedizin Berlin to investigate the potential of therapeutic mRNA in autoimmune disease

25 July, 2022 Uncategorized

Meet Pantherna Therapeutics at BIO-Europe 2022

11 January, 2022 Uncategorized

Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs 

15 November, 2021 Allgemein

Astellas and Pantherna Enter into Technology Evaluation Agreement for Research of mRNA-based Regenerative Medicine.

28 May, 2021 Allgemein

Pantherna Therapeutics to be granted 2.2 millions EFRE public funding.

12 June, 2020 Allgemein

Pantherna Therapeutics GmbH signs an agreement for technology evaluation with Astellas Innovation Management LLC to evaluate Pantherna’s lipid nanoparticle transport system and mRNA molecules.

02 April, 2020 Allgemein

Successful follow-up financing for Pantherna Therapeutics’ development programs to fight Acute Respiratory Distress Syndrome

26 March, 2020 Allgemein

Pantherna Therapeutics GmbH and PROVIREX Genome Editing Therapies GmbH are developing lipid-based delivery systems for mRNA-directed genome editing of lymphocytes for the treatment of HIV and other life-threatening persistent viral diseases